Wed Oct 03 2018

STUDY

Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study

In a groundbreaking observational study encompassing 17,312 patients admitted to Copenhagen University Hospital Amager and Hvidovre, Denmark, a recent publication in the esteemed Critical Care Medicine journal has unveiled promising insights. The study explores how the integration of suPAR (soluble urokinase plasminogen activator receptor) with the National Early Warning Score (NEWS) could revolutionize risk assessment in acute medical cases.

Traditional triage methods, such as NEWS, have long been the cornerstone of emergency departments worldwide. However, this study ventured to ascertain whether supplementing this approach with suPAR measurements could yield more accurate risk stratification.

The findings reverberate with significance: the amalgamation of suPAR and NEWS remarkably bolsters risk prediction for both low- and high-risk acute medical patients. This synergistic approach holds the potential to prompt timely clinical interventions for patients who might not have been initially flagged as urgent, thereby translating to potential life-saving measures.

Particularly intriguing is the role of suPAR as a potent predictor of mortality, especially among patients not displaying overt clinical indicators of deterioration risk. Even in cases where NEWS appears low, elevated suPAR levels correlate with comparable mortality risks seen in patients with higher NEWS scores.

Evidently, the suPAR level rises correspondingly with increasing NEWS scores, asserting its independent prowess in prognosticating mortality risk across the entire NEWS spectrum. This revelation adds an additional layer of predictive value to the NEWS system.

In essence, this study showcases the power of merging established protocols like NEWS with innovative biomarkers like suPAR. The implications are profound – a potential paradigm shift in acute patient care, enabling medical professionals to swiftly identify those in need, intervene promptly, and ultimately make a tangible difference in saving lives.

900+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates